Tolemy Bio Secures €1.4M for AI-Driven Cell Biology
Tolemy Bio has closed a €1.4M pre-seed round led by Norrsken Evolve to develop Orbit, an AI-native platform designed to systematize cell biology research. The funding will support product development, data integrations with partner labs, and early commercial deployments aimed at small and mid-sized biopharma companies.
Orbit: Solving Biopharma’s Data Bottleneck
Orbit functions as an AI control panel for cell biology. Rather than treating experiments as one-off outputs, Orbit captures experimental context and instrumentation data to create reusable representations of cell systems. This approach helps teams predict cell behavior, reduce variability in product quality, and improve manufacturability for cell-based therapeutics.
AI for Reusable Intelligence & Industry Integration
At its core, Orbit combines three capabilities: consolidated lab data ingestion, virtual cell models that simulate biological responses, and research agents that propose next-step experiments. By integrating heterogeneous lab data, the platform turns raw experiment records into structured intelligence that can be queried and applied across projects. Founders and early team members bring academic and engineering experience from leading institutions, and Tolemy has forged partnerships with MIT, University of Cambridge, Anthony Nolan, and GeminiBio to validate models and refine workflows.
Strategic Growth and Market Positioning
Tolemy Bio positions itself as AI infrastructure rather than a single-use tool, targeting organizations that lack the resources to build bespoke machine learning stacks. That stance aims to democratize advanced AI capabilities for smaller biopharma firms, offering a practical layer that sits on top of existing lab workflows. Investor interest, represented by Norrsken Evolve, reflects confidence in the company’s focus on long-term, reusable data assets and industry integration.
By turning dispersed experimental outputs into reusable intelligence, Tolemy Bio hopes to help biopharma teams shorten development cycles and improve reproducibility across cell-based projects.
